Skip to main content

Table 2 Demographic data, clinical manifestations and treatments in patients with scrotal involvement at first episode compared to those without this condition in 149 IgA vasculitis patients

From: Characterization of scrotal involvement in children and adolescents with IgA vasculitis

Variables at diagnosis, n (%)

With scrotal involvement

(n = 27)

Without scrotal involvement

(n = 122)

Demographic data

 Age at diagnosis, years

4.0 (2.0–12.0)

6.0 (1.3–13.0)

 Body mass index, kg/m2, n = 139

16.4 (13.2–20.3)

16 (12.5–32.7)

Clinical/laboratorial involvements

 Persistent purpura/petechiae, n = 146

6/27 (22)

25/119 (21)

 Recurrent purpura/petechiae

7 (26)

20 (16)

 Purpura/petechiae duration, days, n = 140

18.5 (5–60)

14 (1–120)

 Arthritis/arthralgia

21 (78)

95 (77)

 Recurrent arthritis/arthralgia

1 (4)

6 (5)

 Arthritis/arthralgia duration, days, n = 100

4 (2–13)

6 (1–113)

 Abdominal pain

20 (74)

73 (59)

 Recurrent abdominal pain, n = 149

3/26 (12)

16/123 (13)

 Severe abdominal pain, n = 92

7/20 (35)

26/72 (36)

 Abdominal pain duration, days, n = 83

4.5 (1–40)

5 (1–60)

 Gastrointestinal bleeding, n = 149

6/27 (22)

23/122 (19)

 Bowel intussusception

0 (0)

1 (0.8)

 Nephritis, n = 147

10/27 (37)

56/120 (47)

 Arterial hypertension, n = 122

4/22 (18)

16/100 (16)

 Nephrotic syndrome, n = 147

0/26 (0)

3/121 (3)

 Acute kidney injury, n = 145

0/27 (0)

2/118 (2)

 Leukocyturia, n = 146

0/27 (0)

14/119 (12)

 Urinary casts, n = 146

2/27 (7)

13/119 (11)

 Hematuria, n = 146

7/27 (26)

39/119 (33)

 Proteinuria, n = 108

5/17 (29)

34/91 (37)

 Neuropsychiatric involvement

0 (0)

1 (1)

 Increased serum IgA, n = 76

2/11 (18)

37/65 (57)*

Treatments

 Prednisone

25 (93)

60 (49)*

 Intravenous metilprednisolone

0 (0)

1 (1)

 Prednisone dose, mg/kg/day, n = 72

2 (0.5–2)

1 (0.2–30)

 Glucorticosteroid duration, days, n = 76

47.5 (7–140)

37.5 (1–240)

 Ranitidine, n = 149

17/27 (63)

37/122 (30)*

 Ranitidine duration, days, n = 57

35 (2–90)

60 (5–425)

 Immunosuppressive agents

0 (0)

0 (0)

 IVIG

1 (4)

1 (1)

  1. Results are presented as median (minimum value - maximum value) or n (%), increased serum IgA (> 255 mg/dL), IVIG - intravenous immunoglobulin, *p value < 0.05 and the other comparisons between two groups were non-significant